Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
Naturl Alt Intl (NAII) delivers science-backed nutritional solutions through advanced manufacturing and strategic partnerships. This news hub provides investors and industry professionals with essential updates on the company's operational milestones, product innovations, and market positioning.
Access authoritative reporting on NAII's financial disclosures, regulatory achievements, and clinical research collaborations. Our curated collection includes earnings reports, manufacturing capacity expansions, patent filings, and quality assurance certifications - all critical for evaluating the company's industry leadership.
Key updates cover formulation advancements, production facility upgrades, and partnership agreements with healthcare organizations. Track NAII's progress in developing condition-specific supplements while maintaining compliance with global regulatory standards.
Bookmark this page for streamlined access to NAII's latest developments in private-label manufacturing and nutritional science. Check regularly for verified updates that matter to stakeholders in the nutraceuticals sector.
Natural Alternatives International (NAII) and CarnoSyn® Brands have published positive clinical trial results for TriBsyn™, their new encapsulated low-dose β-alanine complex. The study, published in Food Hydrocolloids for Health, demonstrated that TriBsyn™ achieved 4.5-fold higher plasma β-alanine levels compared to conventional β-alanine supplementation.
The randomized, double-blind study revealed that a 400mg dose of TriBsyn™ outperformed both 400mg and 1200mg doses of conventional beta-alanine. Notably, TriBsyn™ eliminated paresthesia, a common side effect, scoring 0.62 on the Visual Analogue Score compared to 2.02 and 4.01 for conventional doses.
The patent-pending formulation uses proprietary Hydro Oleo technology, enabling absorption through multiple pathways including direct cellular uptake and gastrointestinal routes. The product aims to improve muscle vitality, working capacity, and cognitive performance, targeting active aging populations, GLP-1 users, and those following plant-based diets.
Natural Alternatives International (NAII) reported Q2 fiscal 2025 results with a net loss of $2.2 million ($0.37 per share) on net sales of $34.1 million, compared to a $3.1 million loss ($0.52 per share) in Q2 fiscal 2024. Net sales increased 35% year-over-year, driven by a 40% growth in private-label contract manufacturing to $32.3 million.
CarnoSyn® beta-alanine revenue decreased 18% to $1.8 million in Q2. For the first six months of fiscal 2025, the company reported a net loss of $4.2 million on sales of $67.2 million, with sales up 14% from the prior year. The company expects continued losses through fiscal 2025.
As of December 31, 2024, NAII had $8.7 million in cash, working capital of $36.9 million, and $5.0 million in outstanding borrowings against its $10.8 million credit facility.
Natural Alternatives International (NAII) reported Q1 2025 financial results with a net loss of $2.0 million ($0.33 per share) on net sales of $33.2 million, compared to a net loss of $0.7 million in Q1 2024. Sales decreased 2.4% year-over-year, with private-label contract manufacturing down 4.8%. However, CarnoSyn® beta-alanine revenue increased 41.6% to $2.5 million. The company faced operational losses due to reduced sales, changes in sales mix, and increased manufacturing costs. As of September 30, 2024, NAII had $10.1 million in cash and $38.0 million in working capital, with $5.4 million in outstanding borrowings.
CarnoSyn® Brands and Natural Alternatives International (NAII) have announced a new distribution partnership with B&D Nutritional Ingredients, effective October 1st, 2024. Under the agreement, B&D will distribute NAI's new carnosine booster, TriBsyn™, to U.S.-based nutritional supplement, functional food, and beverage markets. TriBsyn™ is a patent-pending ingredient that increases beta-alanine bioavailability while eliminating paresthesia sensation. The product targets various consumer segments including older adults, vegetarians, and vegans seeking to boost their carnosine levels.
Natural Alternatives International (NAI) and CarnoSyn® Brands will showcase TriBsyn™, a patent-pending formula, at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy from September 7-10, 2024. TriBsyn™ utilizes proprietary technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia associated with high doses of beta-alanine.
The team will be at stand #16 to discuss the latest clinical evidence of TriBsyn™, which offers opportunities for various consumer groups, including older adults and vegans. Aaron Starr, VP of CarnoSyn® Brands, highlighted the product's potential in addressing the growing demand for healthy aging and wellness solutions. The team will also attend the 20th European Geriatric Medicine Society Congress in Valencia, Spain on September 18-20.
Natural Alternatives International (NAI) has unveiled TriBsyn™, a revolutionary carnosine booster under its CarnoSyn® Brands portfolio. This groundbreaking product utilizes CarnoSyn® beta-alanine and patent-pending technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia, a common side effect. TriBsyn™ improves beta-alanine absorption by more than four times compared to conventional forms, allowing for lower dosages and increased formulation flexibility.
The product aims to support general wellness, including cognitive performance, muscle function in older adults, and slowing age-related health decline. NAI plans to launch TriBsyn™ commercially at the 46th ESPEN Congress in Milan, Italy, in September. The company expects this innovation to strengthen its presence in dietary supplement categories and fortified and medical foods markets, particularly targeting the aging population and those with plant-based diets.
Natural Alternatives International (NAII) announced its fiscal 2024 Q3 results, revealing a net loss of $1.6 million, or ($0.27) per diluted share, on net sales of $25.1 million. This compares to a $2.4 million net loss in Q3 of the prior year. Q3 net sales fell by 23%, driven by a 26% decrease in private-label contract manufacturing sales. However, CarnoSyn® beta-alanine revenue rose 13% to $2.7 million. For the nine months ending March 31, 2024, NAII reported a net loss of $5.3 million on net sales of $84.3 million, a 29% decrease year-over-year. Cash reserves stood at $12.4 million, with zero outstanding on their credit facility. The company expects to report a net loss for Q4 and fiscal 2024 due to ongoing market adjustments but forecasts future sales growth and a return to profitability with the reopening of their Carlsbad facility in May 2024.
